Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.

Patients with extranodal disease showed a trend for better PFS in the BV cohort with a HR of 0.65 (95% CI, 0.41-1.03; P = .067) but this was not significant.

also in 53,322 other papers

Influence of BV dose and salvage chemotherapy schedule Within the whole BV cohort (unmatched data set; BV cohort, n = 386), subgroup analysis shows a nonsignificant trend for a higher PFS (HR, 0.72; 95% CI; 0.50-1.04; P = .079) in studies that used BV with a combination of chemotherapeutic agents, for example, dexamethasone, high-dose cytarabine, and cisplatin, ICE, or etoposide, methylprednisolone, cisplatin and cytarabine (ESHAP), vs a single agent, for example, bendamustine or gemcitabine ( supplemental Table 6 ). 16 , 17 , 21 , 24 The use of a sequential schedule (ie, BV monotherapy followed by chemotherapy), the number of BV cycles, and the cumulative BV dose did not have an impact on 3-year PFS or pre-ASCT CMR rate between studies in the BV cohort.

also in 5,406 other papers